News

miRagen Therapeutics, Inc. announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. Cobomarsen is…
Read More...

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced that it has obtained authorization to launch its phase…
Read More...

Bavarian Nordic A/S announced the signing of an agreement with AdaptVac, a joint venture established by ExpreS2ion Biotechnologies and NextGen Vaccines spun out of the University of…
Read More...

Daiichi Sankyo Company, Limited and Gustave Roussy today announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and…
Read More...

Evotec SE announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and…
Read More...

Altimmune, Inc. announced that the Company has entered into an agreement with Vigene Biosciences to manufacture AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for…
Read More...

Nexelis, a portfolio company of Ampersand Capital Partners and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and…
Read More...

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020…
Read More...

The inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum successfully concluded in Shanghai on July 17, at which more than 700 authoritative…
Read More...

GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based…
Read More...

ACADIA Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin)…
Read More...

Gilead Sciences, Inc. announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privately held company developing…
Read More...

Jnana Therapeutics announced a strategic, multi-target collaboration and license agreement with Roche for the discovery of small molecule drugs directed at the solute carrier (SLC)…
Read More...

Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, and ImaginAb, Inc., a company that harnesses the specificity of monoclonal…
Read More...

XyloCor Therapeutics announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of…
Read More...

Mateon Therapeutics announced the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research Alliance…
Read More...

JW Therapeutics announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS antibody TCR and solid tumor technology…
Read More...

Tonix Pharmaceuticals Holding Corp. announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to…
Read More...

Catalent and Humanigen, Inc. announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab,…
Read More...

Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced a clinical trial collaboration agreement with Merck,…
Read More...